FDA Will Take Action On Biosimilars Delayed By Inspection Lag

US Agency Says It Is ‘Actively Working’ On Addressing Outstanding Inspections

 
• By Dave Wallace

With multiple US biosimilar applications held up by the FDA’s inability to conduct necessary inspections in the context of the COVID-19 pandemic, the agency tells Generics Bulletin that it is “actively working” on a solution.

COVID-19 coronavirus tape barrier
The pandemic has acted as a barrier to FDA inspections • Source: Alamy

The US Food and Drug Administration is “actively working” on addressing barriers to inspections caused by the COVID-19 pandemic that have resulted in delays to agency action on products including multiple biosimilars, the regulator has told Generics Bulletin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products